

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 09/802,285		ATTY. DOCKET NO.: M0656/7063	
		FILING DATE: March 8, 2001			
		APPLICANT: Liu et al.			
		GROUP ART UNIT: 1614		EXAMINER: Unassigned	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
85	B10	EP	0 244 236	A2	Novo Industri A/S	11/04/1987	
	B11	EP	0 394 971	A1	KabiVitrum AB	10/31/1990	
	B12	WO	92/01003	A1	Board of Regents Univ. of TX System	01/23/1992	
	B13	WO	93/05167	A1	Children's Medical Center Corp.	03/18/1993	
	B14	WO	94/12618	A1	Massachusetts Institute of Technology	06/09/1994	
	B15	WO	95/13830	A1	Massachusetts Institute of Technology	05/26/1995	
	B16	WO	96/01648	A1	Ibex Technologies R and D, Inc.	01/25/1996	
	B17	PCT	US01/70/464		Invitation to Pay Additional Fees	03/08/2001	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
85	C49	AMEER, G.A. et al., "A New Approach to Regional Heparinization: Design and Development of a Novel Immobilized Heparinase Device", <i>Blood Purification Meeting Info: Third International Conference on Continuous Renal Replacement Therapies, San Diego, CA, USA, March 5-7, 1998, Pages 107-108, Vol. 16, No. 2, Abstract</i>	
	C50	BERRY, D. et al., "Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors", <i>The FASEB Journal Express Article 10.1096/jf.00-0661fe</i> , Published online April 6, 2001, Pages 1-19	
	C51	ERNST, S. et al., "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1995, Pages 387-444, Vol. 30, No. 5, CRC Press, Inc.	
	C52	MURPHY, P.R. et al., "Basic fibroblast growth factor binding and processing by human glioma cells", <i>Molecular and Cellular Endocrinology</i> , 1995, Pages 193-203, Vol. 114, No. 1-2, Elsevier Science Ireland Ltd.	
	C53	NATKE, B. et al., "Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation", <i>Angiogenesis</i> , 1999, Pages 249-257, Vol. 3, No. 3, Kluwer Academic Publishers Netherlands	
	C54	PADERA, R. et al., "FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling", <i>The FASEB Journal</i> , October 1999, Pages 1677-1687, Vol. 13, No. 13	

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>Nov 24, 2004</i>
-----------------------------	-------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

579136.1

PAGE 2/3 * RCVD AT 11/15/2004 4:33:08 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/26 * DNIS:2730943 * CSID: * DURATION (mm:ss):01:16